

**BACTERIOSTATIC SODIUM CHLORIDE- bacteriostatic sodium
chloride injection, solution**
HF Acquisition Co LLC, DBA HealthFirst

BACTERIOSTATIC 0.9% SODIUM CHLORIDE INJECTION, USP 30mL VIAL

BOXED WARNING

WARNING: NOT FOR USE IN NEONATES.

SPL UNCLASSIFIED

Multiple-dose Plastic Vial

Multiple-dose LifeShield™ Plastic Vial

NOT FOR INHALATION

DESCRIPTION

This preparation is designed for parenteral use only after addition of drugs that require

dilution or must be dissolved in an aqueous vehicle prior to injection.

Bacteriostatic 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride in water for injection. Each milliliter (mL) contains sodium chloride 9 mg and 0.9% (9 mg/mL) benzyl alcohol added as a bacteriostatic preservative. May contain hydrochloric acid for pH adjustment. It is supplied in a multiple-dose container from which repeated withdrawals may be made to dilute or dissolve drugs for medication. The pH is 5.0 (4.5 to 7.0).

Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.

CLINICAL PHARMACOLOGY

Sodium chloride in water dissociates to provide sodium (Na⁺) and chloride (Cl⁻) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance.

The distribution and excretion of sodium (Na⁺) and chloride (Cl⁻) are largely under the control of the kidney which maintains a balance between intake and output.

The small volume of fluid and amount of sodium chloride provided by Bacteriostatic 0.9% Sodium Chloride Injection, USP, when used only as a vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in neonates and very small infants.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na⁺) plays a major role in maintaining physiologic equilibrium.

INDICATIONS & USAGE

This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

CONTRAINDICATIONS

Due to the potential toxicity of benzyl alcohol in neonates, solutions containing benzyl alcohol must not be used in this patient population.

Parenteral preparations with benzyl alcohol should not be used for fluid or sodium chloride replacement.

Parenteral preparations containing benzyl alcohol should not be used in epidural or spinal anesthetic procedures.

WARNINGS

Benzyl alcohol, a preservative in Bacteriostatic Sodium Chloride Injection, USP has been associated with toxicity in neonates. Data are unavailable on the toxicity of other preservatives in this age group. Preservative-free Sodium Chloride Injection should be used for flushing intravascular catheters. Where a sodium chloride solution is required for preparing or diluting medications for use in neonates, only preservative-free Sodium Chloride Injection should be used.

PRECAUTIONS

Consult the manufacturer's instructions for choice of vehicle, appropriate dilution or volume for dissolving the drugs to be injected, including the route and rate of injection.

Inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration.

Pregnancy

Animal reproduction studies have not been conducted with Bacteriostatic 0.9% Sodium Chloride Injection, USP. It is also not known whether Bacteriostatic 0.9% Sodium Chloride Injection containing additives can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Bacteriostatic 0.9% Sodium Chloride Injection containing additives should be given to a pregnant woman only if clearly needed.

Pediatric Use

The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. However, due to potential toxicity of benzyl alcohol in neonates, solutions containing benzyl alcohol are contraindicated in this patient population.

Drug Interactions

Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.

Use aseptic technique for single or multiple entry and withdrawal from all containers.

When diluting or dissolving drugs, mix thoroughly and use promptly.

Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.

Do not use unless the solution is clear and seal intact.

ADVERSE REACTIONS

Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination.

Although adverse reactions to intravenous, intramuscular or subcutaneous injection of 0.9% benzyl alcohol are not known to occur in man, experimental studies of small volume parenteral preparations containing 0.9% benzyl alcohol in several species of animals have indicated that an estimated intravenous dose up to 30 mL may be safely given to an adult without toxic effects. Administration of an estimated 9 mL to a 6 kg neonate or infant is potentially capable of producing blood pressure changes.

OVERDOSAGE

Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of sodium chloride or fluid overload except possibly in neonates and very small infants. In the event these should occur, re-evaluate the patient and institute appropriate corrective measures. See PRECAUTIONS and ADVERSE REACTIONS.

DOSAGE & ADMINISTRATION

The volume of the preparation to be used for diluting or dissolving any drug for injection, is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

HOW SUPPLIED

BACTERIOSTATIC 0.9% SODIUM CHLORIDE INJECTION, USP is supplied in the following dosage forms.

NDC 51662-1259-1

BACTERIOSTATIC 0.9% SODIUM CHLORIDE INJECTION, USP 30mL VIAL

HF Acquisition Co LLC, DBA HealthFirst
Mukilteo, WA 98275

Also supplied in the following manufacture supplied dosage forms

Bacteriostatic 0.9% Sodium Chloride Injection, USP is supplied as:

Unit of Sale	Each
NDC 0409-1966-04	NDC 0409-1966-09
Tray of 25	10 mL Multiple-dose Plastic Fliptop Vial
NDC 0409-1966-05	NDC 0409-1966-01
Tray of 25	20 mL Multiple-dose Plastic Fliptop Vial
NDC 0409-1966-07	NDC 0409-1966-02
Tray of 25	30 mL Multiple-dose Plastic Fliptop Vial
NDC 0409-1966-12	NDC 0409-1966-06
Tray of 25	10 mL Multiple-dose LifeShield™ Plastic Fliptop Vial

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA



LAB-1096-1.0

9/2017

PRINCIPAL DISPLAY PANEL, VIAL


30 mL Multiple-dose

Bacteriostatic
0.9% Sodium
Chloride
Injection, USP

Hospira

30 mL Multiple-dose
Bacteriostatic
0.9% Sodium
Chloride
Injection, USP


Rx only NDC 0409-1966-02
NOT FOR INHALATION
WARNING: NOT FOR USE IN NEONATES.
FOR DRUG DILUENT USE ONLY.
Each mL contains sodium chloride 9 mg and benzyl alcohol 9 mg added. Sterile, nonpyrogenic. Cleanse stopper with antiseptic.
Hospira, Inc.
Lake Forest, IL 60045 USA RL-4471



(01) 0 030409 196602 4


30 mL Multiple-dose
Bacteriostatic
0.9% Sodium
Chloride
Injection, USP

Rx only NDC 0409-1966-02
NOT FOR INHALATION
WARNING: NOT FOR USE IN NEONATES.
FOR DRUG DILUENT USE ONLY.
Each mL contains sodium chloride 9 mg and benzyl alcohol 9 mg added. Sterile, nonpyrogenic. Cleanse stopper with antiseptic.
AP/DRUGS/08/2013
M.L.No. 08/VP/AP/2013/F/G
Made in India 946115034
RL-4497



(01) 0 030409 196602 4

Mfd. for: Hospira, Inc.
Lake Forest, IL 60045 USA





BACTERIOSTATIC SODIUM CHLORIDE

bacteriostatic sodium chloride injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51662-1259(NDC:0409-1966)
Route of Administration	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
-----------------	-------------------	----------

SODIUM CHLORIDE (UNII: 451W47IQ8X) (CHLORIDE ION - UNII:Q32ZN48698, SODIUM CATION - UNII:LYR4M0NH37)	SODIUM CHLORIDE	9 mg in 1 mL
-------------------------------------------------------------------------------------------------------------	-----------------	-----------------

Inactive Ingredients

Ingredient Name	Strength
BENZYL ALCOHOL (UNII: LKG8494WBH)	9 mg in 1 mL
HYDROCHLORIC ACID (UNII: QTT17582CB)	
WATER (UNII: 059QF0K00R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51662-1259-1	30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product	09/19/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018800	09/19/2018	

Labeler - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Registrant - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Establishment

Name	Address	ID/FEI	Business Operations
HF Acquisition Co LLC, DBA HealthFirst		045657305	relabel(51662-1259)

Revised: 12/2022

HF Acquisition Co LLC, DBA HealthFirst